CL2007001870A1 - Composicion farmaceutica de dosificacion solida que comprende valsartan, amlodipina, hidroclorotiazida y aditivos farmaceuticamente aceptables; procedimiento de preparacion; y uso para el tratamiento de hipertension, insuficiencia cardiaca, infarto d - Google Patents

Composicion farmaceutica de dosificacion solida que comprende valsartan, amlodipina, hidroclorotiazida y aditivos farmaceuticamente aceptables; procedimiento de preparacion; y uso para el tratamiento de hipertension, insuficiencia cardiaca, infarto d

Info

Publication number: CL2007001870A1
Authority: CL; Chile
Prior art keywords: hydrochlorotiazida; amlodipina; infarto; hypertension; treatment
Prior art date: 2006-06-27

Application number

CL200701870A

Other languages

English (en)

Inventor

Yu Zhu Jianhao Joshi Yatin Cao

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-06-27

Filing date

2007-06-26

Publication date

2008-06-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38662673&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2007001870(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-06-26 Application filed by Novartis Ag filed Critical Novartis Ag

2008-06-13 Publication of CL2007001870A1 publication Critical patent/CL2007001870A1/es

Links

239000004072 C09CA03 - Valsartan Substances 0.000 title 1
206010019280 Heart failures Diseases 0.000 title 1
206010020772 Hypertension Diseases 0.000 title 1
239000000654 additive Substances 0.000 title 1
238000000034 method Methods 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
239000007787 solid Substances 0.000 title 1
SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 title 1
229960004699 valsartan Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Obesity (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Gastroenterology & Hepatology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

CL200701870A 2006-06-27 2007-06-26 Composicion farmaceutica de dosificacion solida que comprende valsartan, amlodipina, hidroclorotiazida y aditivos farmaceuticamente aceptables; procedimiento de preparacion; y uso para el tratamiento de hipertension, insuficiencia cardiaca, infarto d CL2007001870A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US80588306P	2006-06-27	2006-06-27

Publications (1)

Publication Number	Publication Date
CL2007001870A1 true CL2007001870A1 (es)	2008-06-13

Family

ID=38662673

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL200701870A CL2007001870A1 (es)	2006-06-27	2007-06-26	Composicion farmaceutica de dosificacion solida que comprende valsartan, amlodipina, hidroclorotiazida y aditivos farmaceuticamente aceptables; procedimiento de preparacion; y uso para el tratamiento de hipertension, insuficiencia cardiaca, infarto d

Country Status (22)

Country	Link
US (2)	US20100003321A1 (es)
EP (1)	EP2037893A2 (es)
JP (1)	JP2009542709A (es)
KR (1)	KR20090021191A (es)
CN (2)	CN103169711A (es)
AR (1)	AR061627A1 (es)
AU (1)	AU2007265138A1 (es)
BR (1)	BRPI0713785A2 (es)
CA (1)	CA2654986A1 (es)
CL (1)	CL2007001870A1 (es)
EC (1)	ECSP088987A (es)
IL (1)	IL195797A0 (es)
MA (1)	MA30529B1 (es)
MX (1)	MX2008016532A (es)
NO (1)	NO20090314L (es)
NZ (1)	NZ573295A (es)
PE (2)	PE20080991A1 (es)
RU (1)	RU2449786C2 (es)
TN (1)	TNSN08538A1 (es)
TW (1)	TW200808379A (es)
WO (1)	WO2008002905A2 (es)
ZA (1)	ZA200810053B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JO3239B1 (ar)	2008-09-22	2018-03-08	Novartis Ag	تركيبات جالينية من مركبات عضوية
AP2011005795A0 (en)	2009-02-13	2011-08-31	Boehringer Ingelheim Int	SGLT-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia.
US20120107397A1 (en) *	2009-07-03	2012-05-03	Hetero Research Foundation	Pharmaceutical compositions of valsartan
JP5758900B2 (ja)	2009-09-30	2015-08-05	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	グルコピラノシル置換ベンジルベンゼン誘導体の調製方法
UY32919A (es) *	2009-10-02	2011-04-29	Boehringer Ingelheim Int	Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
CN102091069A (zh) *	2009-12-11	2011-06-15	浙江华海药业股份有限公司	缬沙坦和氨氯地平的复方制剂及其制备方法
CN101897675B (zh) *	2010-02-10	2012-11-21	温士顿医药股份有限公司	含有凡尔沙坦或其药学上可接受的盐的固体剂型口服医药组成物
CN101829111B (zh) *	2010-05-23	2014-12-17	浙江华海药业股份有限公司	含有缬沙坦的固体制剂及其制备方法
CN102716132B (zh) *	2011-03-29	2015-09-30	石药集团中奇制药技术（石家庄）有限公司	复方氨氯地平/缬沙坦/氢氯噻嗪片及其制备方法
MX2014007933A (es) *	2011-12-26	2014-07-30	Novartis Ag	Comprimidos y agentes recubiertos en seco.
US9192617B2 (en)	2012-03-20	2015-11-24	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
CN102614190A (zh) *	2012-04-17	2012-08-01	北京哈三联科技股份有限公司	含有缬沙坦、氨氯地平和氢氯噻嗪的片剂及其制备方法
JP6018420B2 (ja) *	2012-06-05	2016-11-02	ニプロ株式会社	アンジオテンシンｉｉ受容体拮抗薬およびサイアザイド系利尿薬を含む医薬組成物
MX358211B (es)	2012-07-23	2018-08-10	Landsteiner Scient S A De C V	Una composición farmacéutica de liberación comprendiendo hidroclorotiazida, losartán y basilato de amlodipino.
CN103655580B (zh) *	2012-08-28	2017-12-01	海南中济医药科技有限公司	一种含有缬沙坦、苯磺酸氨氯地平和氢氯噻嗪的药物组合物及其制备方法
TW201427720A (zh) *	2012-10-12	2014-07-16	Ajinomoto Kk	含有鈣拮抗劑及血管張力素ｉｉ受體拮抗劑之醫藥製劑之製造方法
CN102846625A (zh) *	2012-10-18	2013-01-02	海口华仕联医药科技有限公司	一种稳定的缬沙坦、氨氯地平和氢氯噻嗪的药物组合及其制备方法
US20140303097A1 (en)	2013-04-05	2014-10-09	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en)	2013-04-05	2023-11-14	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
CA2812519A1 (en)	2013-04-05	2014-10-05	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
HRP20190101T1 (hr)	2013-04-05	2019-03-08	Boehringer Ingelheim International Gmbh	Terapeutske uporabe empagliflozina
FI4000608T3 (fi)	2013-04-18	2026-01-21	Boehringer Ingelheim Int	Farmaseuttinen koostumus, menetelmä hoitamiseksi ja sen käyttöjä
CZ2013783A3 (cs)	2013-10-08	2015-04-15	Zentiva, K. S	Stabilní farmaceutická kompozice obsahující amlodipin a valsartan
CN105106962A (zh) *	2015-08-29	2015-12-02	西安力邦肇新生物科技有限公司	一种复方降压制剂及其应用
JP6411662B2 (ja) *	2016-05-30	2018-10-24	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	固定容量配合剤
KR20250097990A (ko)	2016-11-10	2025-06-30	베링거 인겔하임 인터내셔날 게엠베하	약제학적 조성물, 치료 방법 및 이의 용도
KR102568472B1 (ko)	2017-02-27	2023-08-18	이도르시아 파마슈티컬스 리미티드	엔도텔린 관련 질환의 치료를 위한 4-피리미딘술파미드 유도체와 활성 성분의 조합물
WO2019008485A1 (en) *	2017-07-06	2019-01-10	Mankind Pharma Ltd	FIXED DOSE PHARMACEUTICAL COMPOSITION BASED ON VALSARTAN AND SACUBITRIL
KR20260037123A (ko)	2017-11-30	2026-03-17	이도르시아 파마슈티컬스 리미티드	엔도텔린 관련 질병의 치료를 위한 sglt-2 저해제와의 4-피리미딘설파미드 유도체의 병용
WO2022132067A1 (en) *	2020-12-18	2022-06-23	Santa Farma Ilac Sanayii A.S.	Stable bilayer tablet compositions
CN113171352A (zh) *	2021-04-15	2021-07-27	海南锦瑞制药有限公司	一种沙坦类降压复方制剂的制备方法
GR1010320B (el) *	2021-08-04	2022-10-11	Win Medica Φαρμακευτικη Ανωνυμη Εταιρεια,	Στερεες φαρμακοτεχνικες μορφες ιρβεσαρτανης, υδροχλωροθειαζιδης και αμλοδιπινης

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6057344A (en) *	1991-11-26	2000-05-02	Sepracor, Inc.	Methods for treating hypertension, and angina using optically pure (-) amlodipine
EP0795327A1 (en) *	1996-03-13	1997-09-17	Pfizer Inc.	Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin
RU2188636C2 (ru) *	1998-03-26	2002-09-10	Др. Редди'С Лабораторис Лтд.	Стабильный фармацевтический препарат, содержащий амлодипина безилат и атенолол
US20040087484A1 (en) *	2000-12-01	2004-05-06	Sahota Pritam Singh	Combination of organic compounds
US20030152622A1 (en) *	2001-10-25	2003-08-14	Jenny Louie-Helm	Formulation of an erodible, gastric retentive oral diuretic
CN101352421A (zh) *	2002-01-16	2009-01-28	贝林格尔英格海姆法玛两合公司	一种制备基本上非结晶形式的替米沙坦的方法
US6869970B2 (en)	2002-02-04	2005-03-22	Novartis Ag	Crystalline salt forms of valsartan
AUPS236902A0 (en) *	2002-05-16	2002-06-13	Northern Sydney Area Health Service	Composition and method for treating hypertension
EG24716A (en) *	2002-05-17	2010-06-07	Novartis Ag	Combination of organic compounds
KR100580168B1 (ko)	2003-03-21	2006-05-16	삼성전자주식회사	다중 홈 에이전트 제어장치 및 방법
US20050187262A1 (en)	2004-01-12	2005-08-25	Grogan Donna R.	Compositions comprising (S)-amlodipine and an angiotensin receptor blocker and methods of their use
ES2385832T3 (es)	2004-05-21	2012-08-01	Accu-Break Technologies, Inc.	Comprimidos farmacéuticos que presentan un segmento relativamente inactivo
CN103083318A (zh) *	2004-11-05	2013-05-08	贝林格尔.英格海姆国际有限公司	包含替米沙坦和氨氯地平的双层片剂
CN100389830C (zh) *	2005-05-08	2008-05-28	广州市施柏医药科技有限公司	一种治疗高血压的药物组合物

2007
- 2007-06-25 PE PE2007000810A patent/PE20080991A1/es not_active Application Discontinuation
- 2007-06-25 PE PE2011001722A patent/PE20120542A1/es not_active Application Discontinuation
- 2007-06-25 AR ARP070102798A patent/AR061627A1/es not_active Application Discontinuation
- 2007-06-26 CN CN2013100435988A patent/CN103169711A/zh active Pending
- 2007-06-26 EP EP07799032A patent/EP2037893A2/en not_active Ceased
- 2007-06-26 WO PCT/US2007/072097 patent/WO2008002905A2/en not_active Ceased
- 2007-06-26 AU AU2007265138A patent/AU2007265138A1/en not_active Abandoned
- 2007-06-26 CL CL200701870A patent/CL2007001870A1/es unknown
- 2007-06-26 NZ NZ573295A patent/NZ573295A/en not_active IP Right Cessation
- 2007-06-26 KR KR1020087031581A patent/KR20090021191A/ko not_active Ceased
- 2007-06-26 CN CN200780024142XA patent/CN101478956B/zh active Active
- 2007-06-26 CA CA002654986A patent/CA2654986A1/en not_active Abandoned
- 2007-06-26 RU RU2009102273/15A patent/RU2449786C2/ru not_active IP Right Cessation
- 2007-06-26 US US11/915,096 patent/US20100003321A1/en not_active Abandoned
- 2007-06-26 BR BRPI0713785-0A patent/BRPI0713785A2/pt not_active IP Right Cessation
- 2007-06-26 MX MX2008016532A patent/MX2008016532A/es not_active Application Discontinuation
- 2007-06-26 JP JP2009518503A patent/JP2009542709A/ja active Pending
- 2007-06-26 TW TW096123057A patent/TW200808379A/zh unknown
2008
- 2008-11-26 ZA ZA200810053A patent/ZA200810053B/xx unknown
- 2008-12-08 IL IL195797A patent/IL195797A0/en unknown
- 2008-12-18 EC EC2008008987A patent/ECSP088987A/es unknown
- 2008-12-24 MA MA31506A patent/MA30529B1/fr unknown
- 2008-12-26 TN TNP2008000538A patent/TNSN08538A1/en unknown
2009
- 2009-01-20 NO NO20090314A patent/NO20090314L/no not_active Application Discontinuation
2012
- 2012-01-03 US US13/342,533 patent/US8475839B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
TW200808379A (en)	2008-02-16
CN101478956B (zh)	2013-03-20
NZ573295A (en)	2012-01-12
RU2449786C2 (ru)	2012-05-10
MX2008016532A (es)	2009-01-19
MA30529B1 (fr)	2009-06-01
JP2009542709A (ja)	2009-12-03
HK1133818A1 (en)	2010-04-09
IL195797A0 (en)	2009-09-01
US8475839B2 (en)	2013-07-02
US20120164218A1 (en)	2012-06-28
NO20090314L (no)	2009-01-26
ECSP088987A (es)	2009-01-30
CN103169711A (zh)	2013-06-26
TNSN08538A1 (en)	2010-04-14
US20100003321A1 (en)	2010-01-07
PE20120542A1 (es)	2012-05-14
WO2008002905A3 (en)	2008-12-11
CN101478956A (zh)	2009-07-08
WO2008002905A2 (en)	2008-01-03
CA2654986A1 (en)	2008-01-03
ZA200810053B (en)	2009-11-25
BRPI0713785A2 (pt)	2012-10-30
EP2037893A2 (en)	2009-03-25
AU2007265138A1 (en)	2008-01-03
RU2009102273A (ru)	2010-08-10
KR20090021191A (ko)	2009-02-27
PE20080991A1 (es)	2008-09-05
AR061627A1 (es)	2008-09-10

Publication	Publication Date	Title
CL2007001870A1 (es)	2008-06-13	Composicion farmaceutica de dosificacion solida que comprende valsartan, amlodipina, hidroclorotiazida y aditivos farmaceuticamente aceptables; procedimiento de preparacion; y uso para el tratamiento de hipertension, insuficiencia cardiaca, infarto d
CL2007002018A1 (es)	2008-05-09	Compuestos derivados de isoxazolinas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para el tratamiento de una enfermedad causada por un aumento en la proliferacion celular.
CL2007002689A1 (es)	2008-04-18	Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
BRPI0818193A2 (pt)	2017-12-12	composto, sal farmacêuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto
CL2013001885A1 (es)	2014-03-28	Compuestos derivados de morfina, antagonistas del receptor ipiode periferico; composicion farmaceutica; formulacion oral; y uso para reducir los efectos colaterales de la terapia opioide (div. sol. 905-08).
BRPI0917540A2 (pt)	2015-11-17	composto, sal farmacologicamente aceitavél, composição farmacêutica, e, uso de um composto ou sal farmacologicamente aceitável
CL2007001993A1 (es)	2008-06-20	Compuestos derivados de pirimidilciclopentanos hidroxilados y metoxilados; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodegenerat
CL2009000349A1 (es)	2010-02-19	Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
BRPI0917315A2 (pt)	2015-11-17	anticorpo, composicao farmaceutico, e, uso de uma composicao farmaceutica
CL2007002188A1 (es)	2008-02-01	Compuestos derivados de heteroarilaminas; procedimiento de preparacion; composicion farmceutica; y uso del compuesto para tratar el crecimiento celular anormal.
BRPI0821115A2 (pt)	2015-06-16	Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
CL2008000127A1 (es)	2008-05-23	Compuestos derivados de n-(heteroaril)-1-heteroaril-1h-indol-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor, inflamacion, trastornos urologicos
BRPI0806531A2 (pt)	2014-04-22	Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
CL2007001992A1 (es)	2008-07-18	Compuestos derivados de pirimidilciclopentanos; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodege
BRPI0816320A2 (pt)	2015-03-24	Composto, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto de combinação, e, processos para a preparação deu um composto, de uma formulação farmacêutica, e de um produto de combinação
CL2007001918A1 (es)	2008-03-28	Compuestos derivados heteroarilos sustituidos; metodo para la preparacion de los compuestos; composicion farmaceutica; y uso para el tratamiento del dolor, depresion, enfermedad de alzheimer e hipertension entre otras.
CL2007002891A1 (es)	2008-04-18	Trans-5-cloro-2-metil-2,3,3a,12b-tetrahidro-1h-dibenz-[2,3:6,7]oxepino[4,5-c]pirrol 50% amorfo en base al peso total del compuesto; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de un trastorno seleccionado entre e
BRPI0906576A2 (pt)	2015-07-07	Composição farmacêutica, kit, uso de um composto, e, agente terapêutico para câncer
CL2008002295A1 (es)	2009-03-27	Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
BRPI0812738A2 (pt)	2014-09-30	Composto, sal farmceuticamente aceitável, composição farmacêutica, uso de um composto, e, método par ao tratamento de uma infecção viral em um humano
BRPI1009392A2 (pt)	2016-03-08	"formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica."
BRPI0911203A2 (pt)	2016-07-05	peptídeo ou derivado de peptídeo, composição farmacêutica, uso de um peptídeo ou derivado de peptídeo, métodos para tratar um paciente tendo uma deficiencia e para preparar o peptídeo ou derivado de peptídeo.
BR112012003280A2 (pt)	2017-05-23	composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto.
CL2007001630A1 (es)	2008-02-08	Compuestos derivados de pirrolidinamida; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
CL2008000059A1 (es)	2008-07-18	Compuestos derivados de espiropiperidina-glicinamida; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hipertension, dismenorrea, fallo cardiaco cronico, ansiedad, t